| Wednesday
| Thursday | Friday
| Saturday |
| SUNDAY,
DECEMBER 16, 2007 |
| 7:00-9:00 |
POSTER
SESSION 6 & CONTINENTAL BREAKFAST– Exhibit Hall
B
(#6001-6119) |
| |
 |
|
| |
Prognosis and Response Prediction |
| |
Prognostic Factors
II |
6001-6034 |
| |
Epidemiology and Outreach |
| |
Advocacy/Education
Epidemiology
|
6035-6046
6047-6060 |
| |
Treatment |
| |
Chemotherapy - New Drugs and Formulations
Other Therapies
Patient Management
|
6061-6074
6075-6086
6087-6098 |
| |
Tumor Cell Biology |
| |
Molecular Biology
Genetics |
6099-6111
6112-6119 |
| |
|
| 9:00-12:00 |
GENERAL SESSION 7– Exhibit Hall D |
| |
Jenny Chang, MD, Co-Moderator
Baylor College of Medicine,
Houston, TX
and
Lisa Carey, MD
University of North Carolina,
Chapel Hill, NC |
| |
|
| 9:00 |
71. Disease-free survival according to local immunohistochemistry for HER2 and central fluorescence in situ hydridization for patients treated with adjuvant chemotherapy with and without trastuzumab in the HERA (BIG 01-01) trial.
McCaskill-Stevens W, Procter M, Goodbrand J, Azambuja E, Leyland-Jones B, Ruschoff J, Dowsett M, Wermuth P, Dolci S, Gelber RD, Piccart-Gebhart M. National Cancer Institute, Bethesda, MD; Frontier Science, Kingussie, United Kingdom; Jules Bordet Institute, Brussels, Belgium; Emory University, Atlanta, GA; Klinikum Kasseland TARGOS Molecular Pathology Gmbh, Kassel, Germany; Hoffmann-La Roche, Basel, Switzerland; Royal Marsden National Health Service Trust, London, United Kingdom; Dana-Farber Cancer Institute, Boston, MA. |
| |
|
| 9:15 |
72. 3-year follow-up of trastuzumab following adjuvant chemotherapy in node positive HER2-positive breast cancer patients: results of the PACS-04 trial.
Spielmann M, Roché H, Humblet Y, Delozier T, Bourgeois H, Serin D, Romieu G, Canon JL, Monnier A, Piot G, Maerevoet M, Orfeuvre H, Extra JM, Hardy AC, Martin AL, Kramar A, Genève J. Inst Gustave Roussy, France; Inst Claudius Régaud, France; UCL St-Luc, Belgium; Centre François Baclesse, France; CHU Poitiers, France; Inst Ste Catherine, Avignon, France; Centre Val d'Aurelle, France; CH ND Reine Fabiola, Belgium; CHG Montbelliard, France; CMC les Ormeaux, Le Havre, France; Clinique St Pierre, Ottignies, Belgium; CH Bourg en Bresse, France; Inst Curie, France; Cl Armoricaine St Brieuc, France; FNCLCC, France. |
| |
|
| 9:30 |
73. Safety of pertuzumab plus trastuzumab in a Phase II trial
of patients with HER2-overexpresing metastatic breast
cancer which had progressed during trastuzumab therapy.
Fumoleau P, Wardley A, Miles D, Verma S, Gelmon K, Cameron
D, Gianni L, Conte PF, Ross G, McNally V, Baselga J. Centre
Georges-François-Leclerc, Dijon, France; Christie Hospital,
Manchester, UK; Mount Vernon Cancer Centre, Middlesex, UK;
Ottawa Regional Cancer Center, Ottawa, ON, Canada; British
Columbia Cancer Agency, Vancouver, BC, Canada; Western
General Hospital, Edinburgh, UK; Oncologia Medica, Milano,
Italy; Divisione di Oncologia Medica, Modena, Italy; *Roche
products limited, Welwyn, UK; Vall d’Hebron University Hospital,
Barcelona, Spain. |
| |
|
| 9:45 |
74. Combination of nab-paclitaxel and bevacizumab eradicates well-established tumors as well as lymphatic and pulmonary metastases in a MDA-MB-231 model of a highly metastatic human breast cancer.
Ran S, Volk L, Bivens C, Trieu V, Desai N. Southern Illinois University, Springfield, IL; Abraxis BioScience, Inc., Los Angeles, CA. |
| |
|
| 10:00 |
75. ErbB-2 inhibition activates notch-1 and sensitizes breast cancer cells to a gamma-secretase inhibitor: opportunity for a novel therapeutic combination.
Osipo C, Patel P, Hao L, Whitehouse L, Strack P, Golde T, Albain K, Miele L. Loyola University Medical Center, Maywood, IL; Merck Research Laboratories, Boston, MA; The Mayo Clinic College of Medicine, Jacksonville, FL.
|
| |
|
| 10:15 |
76. Parity regulates activation of p53 in human breast tissue.
Smith-Schneider S, Crisi GM, Mathews L, Bentley B, Stueber K, Jerry DJ. Baystate Medical Center/Tufts University School of Medicine, Springfield, MA; Pioneer Valley Life Sciences Institute, Springfield, MA; Baystate Medical Center/Baystate Plastic Surgery Associates, Springfield, MA. |
| |
|
| 10:30 |
77. Cytrochrome P450 2D6 activity predicts adherence to
Tamoxifen therapy.
Rae JM, Sikora MJ, Henry NL, Li L, Kim S, Oesterreich S, Skaar
T, Nguyen A, Desta Z, Storniolo AM, Flockhart DA, Hayes DF,
Stearns V for the COBRA investigators. University of Michigan
Comprehensive Cancer Center; University of Michigan School
of Medicine; Indiana University; Baylor College of Medicine;
Johns Hopkins University School of Medicine. COBRA is the
Consortium on Breast Cancer Pharmacogenomics, an NIH
supported Consortium of investigators at these institutions
studying pharmacogenomics in the treatment of breast cancer. |
| |
|
| 10:45 |
78. Preliminary results of the UK Taxotere as Adjuvant Chemotherapy (TACT) Trial.
Ellis PA, Barrett-Lee PJ, Bloomfield D, Cameron DA, Hall E, Johnson L, Johnston SRD, Bliss JM. Guys, Kings & St Thomas's Hospital, London, United Kingdom; Velindre Hospital, Cardiff, Wales, United Kingdom; Royal Sussex County Hospital, Brighton, Sussex, United Kingdom; University of Leeds, Leeds, United Kingdom; Institute of Cancer Research, Sutton, Surrey, United Kingdom; Royal Marsden NHS Foundation Trust, London, United Kingdom. |
| |
|
| 11:00 |
79. Evaluating the efficacy of capecitabine given concomitantly or in sequence to epirubicin/cyclophosphamide → docetaxel as neoadjuvant treatment for primary breast cancer. First efficacy analysis of the GBG/AGO intergroup-study "GeparQuattro".
von Minckwitz G, Rezai M, Loibl S, Fasching P, Huober J, Tesch H, Bauerfeind I, Hilfrich J, Mehta K, Untch M. University Hospital Frankfurt, Frankfurt, Germany; German Breast Group, Neu-Isenburg, Germany; Senologie, Brustzentrum, Düsseldorf, Germany; Frauenklinik mit Poliklinik, Erlangen, Germany; Senologiezentrum Ostschweiz SENZO, St. Gallen, Switzerland; Onkologie Bethanien, Frankfurt, Germany; Frauenklinik, München, Germany; Frauenklinik, Hannover, Germany; Frauenklinik, Berlin, Germany. |
| |
|
| 11:15 |
80. Characterizing the biology and response of locally advanced breast cancer in women undergoing neoadjuvant therapy: preliminary results from the I-SPY trial.
Hylton N, Carey L, DeMichele A, Blume J, Broadwater G, Madhavan S, Rosen M, George S, Esserman L, ISPY Clinical, Research, Pathology and Radiology Investigators. Univ of California San Francisco, San Francisco, CA; Univ of North Carolina, Chapel Hill, NC; Univ of Pennsylvania, Philadelphia, PA; ACRIN, Philadelphia, PA; CALGB, Chapel Hill, NC; NCI-SPORE, Bethesda, MD. |
| |
|
| 11:30 |
81. Elucidating the stem and progenitor cell hierarchy in breast development and cancer - an essential role for GATA-3.
Lindeman GJ, Asselin-Labat M-L, Sutherland KD, Barker H, Thomas R, Shackleton M, Hartley L, Robb L, Grosveld FG, van der Wees J, Visvader JE. The Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia; The Royal Melbourne Hospital, Melbourne, Australia; Erasmus University, Rotterdam, Netherlands. |
| |
|
| 11:45 |
82. Decrease in tumorigenic breast cancer stem cells in primary breast cancers with neoadjuvant lapatinib.
Li X, Creighton C, Wong H, Hilsenbeck SG, Osborne CK, Rosen JM, Lewis MT, Chang JC. Dan L Duncan Cancer Center at Baylor College of Medicine, Houston, TX. |
| |
|
| 12:00 |
ADJOURNMENT, 30th Annual San
Antonio Breast Cancer Symposium |
|
|
|
|
Home
Registration
Schedule at a Glance
